MEDITOXIN® 200u

Description

Name: MEDITOXIN® 200u
Manufacturer: Huons Global Co., Ltd
Active Substance(s): BOTULINUM TOXIN TYPE A
Strength: 200u
Pack Size: 200u – 1 vial
Package Content: 1 x 200 Units Vial

MEDITOXIN® 200u is a purified Botulinum Toxin Type A complex commonly used for both aesthetic and therapeutic applications. It has demonstrated proven efficacy and safety, comparable to OnabotulinumtoxinA, in various clinical studies. Launched in 2006, MEDITOXIN® has been registered in 27 countries and is known by other brand names, including Siax®, Botulift®, Cunox®, and Neuronox®. It is available in 50, 100, and 200 units, offering flexibility for different applications. This product is widely used for the treatment of glabellar frown lines, blepharospasm, cerebral palsy, and upper limb spasticity.

Key Features:

• Global Presence: Registered in 27 countries, with ongoing registrations in 30 additional countries.
• Versatile Usage: Available in 50, 100, and 200 units, suitable for various medical and aesthetic purposes.
• Comparable Safety: Proven to be as safe as OnabotulinumtoxinA in clinical trials.

MEDITOXIN® 200u is presented as a lyophilized white powder for injection, housed in a colorless, transparent vial. It is typically packaged in 50, 100, or 200 units per vial. The drying method used is freeze-drying, ensuring stability and longevity.

Ingredients:

• Clostridium botulinum toxin type A complex: 100 Units
• Human serum albumin: 0.5 mg
• Sodium chloride: 0.9 mg
• Diluent (0.9% sodium chloride): Varies based on concentration.

MEDITOXIN® 200u is indicated for the treatment of benign essential blepharospasm in patients 18 years and older, equinus foot deformity in pediatric cerebral palsy patients 2 years and older, serious glabellar wrinkles in adults aged 18 to 65, and upper limb spasticity after stroke in patients 20 years and older.

Contraindications and Side Effects:

• Contraindications: Hypersensitivity to any components, infection at the injection site.
• Common Side Effects: Eyelid ptosis (3.2%), extraocular muscle disorder (0.6%), localized pain, and swelling.
• Adverse Event Rate: 16.1% with MEDITOXIN® and 27.6% with OnabotulinumtoxinA. No significant differences in safety profiles.

Administration of MEDITOXIN® 200u involves intramuscular injection by a qualified healthcare professional. Dosages vary based on the condition treated. For glabellar lines, a dose of 20 units divided across 5 points is standard. For upper limb spasticity, dosing depends on the muscle group and severity.

Storage:

• Temperature: Keep in a freezer (-5°C or below) or refrigerator (2-8°C).
• Reconstitution: Use 0.9% sodium chloride for dilution.
• Shelf Life: Use within 24 hours after reconstitution.

Warning! The product is intended solely for professional use in a medical environment and under professional supervision. The product is supplied to medical professionals who specialize in aesthetic medicine (plastic surgery, facial treatments) and work under individual medical licenses as aestheticians or in dedicated clinics. Unprofessional use by individuals without a medical background may lead to severe adverse effects and health harm.